Every living creature on Earth needs to protect itself from things that would do it harm. Bacteria are no different. And ...

The CRISPR-Cas9 patent landscape remains complex and unsettled. The Federal Circuit’s latest decision in University of California v.

Scientists at the McGovern Institute and the Broad Institute of MIT and Harvard have reengineered a compact RNA-guided enzyme ...

Researchers at UC Berkeley’s Innovative Genomics Institute, or IGI, developed a revolutionary treatment using CRISPR gene ...

For years, the CRISPR-Cas9 genome technology has been reshaping genetic engineering, a precision tool to transform everything from agriculture to medicine. With its incredible efficiency ...

Here’s how it works. CRISPR, short for CRISPR-Cas9, is a genome-editing tool that allows scientists to precisely cut and modify DNA sequences. It has revolutionized the study of genes ...

The CRISPR-Cas9 platform will be used to delete the PD-1 gene in T cells extracted from trial participant’s blood. In healthy cells, an activated PD-1 gene results in the production of the PD-1 ...

Cas9, the first Cas protein repurposed for cutting DNA, introduces double-strand breaks that recruit DNA repair machinery. Despite its successes, the CRISPR-Cas9 system has several limitations, ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

In a new study published in Nature titled, “Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning,” researchers from Massachusetts General Hospital (MGH) and Harvard ...

The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs ...

1. Du Rand A, Hunt J, Samson C, et al. Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa. Bioeng Transl Med. 2024;9(4):e10640. doi:10.1002/btm2 ...